Stock Comparison
ABBV vs UTHR
AbbVie Inc vs United Therapeutics Corp
Who's the better investment? Let's break it down.
The Verdict
UTHR takes this one.
It's not even close. UTHR outscores ABBV by 4.9 points. That's a significant gap in our deep value framework.
Want to compare any two stocks?
Sign up free — get 3 DVR analyses/day, 1800+ stocks, portfolio roast. No credit card.
Valuation
ABBV
Metric
UTHR
Market Cap
P/E Ratio
Lower may indicate better value
Forward P/E
Price/Book
Profitability & Growth
ABBV
Metric
UTHR
Profit Margin
Gross Margin
Operating Margin
Return on Equity
Return on Assets
Revenue Growth
EPS
Financial Health
ABBV
Metric
UTHR
Debt-to-Equity
Lower = less leverage
Current Ratio
Above 1.0 is healthy
Beta
Lower = less volatile
Dividend Yield
Risk Comparison
ABBV
What Could Go Wrong
AbbVie's future growth relies heavily on the continued success and market share expansion of its next-generation immunology drugs, Skyrizi and Rinvoq, which together are projected to reach over $32 bi...
Red Flags
- 🚩Insider Selling Activity: 4 insider sales and 0 purchases in the last 6 months, as per the Quiver so...
- 🚩High R&D Investment for Uncertain Returns: While inherent to pharma, the substantial R&D expenditure...
- 🚩GAAP EPS Volatility: The Q1 2026 GAAP diluted EPS of $0.39, a -45.8% YoY decline due to an unfavorab...
UTHR
What Could Go Wrong
The biggest risk is the continued commercial underperformance of key therapies, as evidenced by the Q1 2026 revenue miss of $15.9 million against estimates, potentially indicating weaker-than-expected...
Red Flags
- 🚩Q1 2026 revenue and EPS miss ($781.5M revenue vs $797.4M est.; $5.82 EPS vs $7.00 est.) indicating c...
- 🚩HC Wainwright cut Q2 2026 EPS estimate to $6.07 from $6.76 on May 18, 2026, signaling a more cautiou...
- 🚩Insider selling by CFO James Edgemond ($5.73M on May 26, 2026) and General Counsel Paul A. Mahon (mi...
Competitive Moat
ABBV
Rating
🛡️ Wide
Trend
➡️ Stable
UTHR
Rating
🛡️ Narrow
Trend
📈 Expanding
Investment Thesis
If AbbVie's key immunology drugs, Skyrizi and Rinvoq, continue to expand their market share globally and achieve their projected combined annual revenue of over $32 billion by 2027, complemented by successful advancements in its neuroscience and oncology pipelines, then the company will sustain mid-to-high single-digit revenue growth and generate substantial free cash flow, supporting its robust d...
Full ABBV AnalysisIf United Therapeutics successfully executes the commercial launch and market penetration of Ralinepag and continues to expand the Tyvaso franchise through new formulations and indications, then the company could achieve a sustainable mid-to-high single-digit revenue growth rate annually, leading to EPS growth that justifies a premium valuation multiple. This is bullish because the market may be u...
Full UTHR AnalysisPrice Targets & Strategy
Price Targets & Entry/Exit Strategy
Sign up free to unlock the full comparison
Growth Catalysts
Growth Catalysts Comparison
Sign up free to unlock the full comparison
Market Sentiment
Market Sentiment Analysis
Sign up free to unlock the full comparison
The Deep Dive
AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the mature, highly regulated nature of the pharmaceutical industry inherently preclude the possibility of ...
Full ABBV AnalysisUnited Therapeutics continues to present a compelling long-term narrative driven by its robust pipeline, particularly with the positive Phase 3 results for Ralinepag and Tyvaso nebulized treprostinil, expanding its addressable markets in pulmonary hypertension and idiopathic pulmonary fibrosis. The company maintains a strong balance sheet with healthy cash flow generation. However, achieving a 10x market capitalization ($236.4 billion) within 3-5 years remains highly improbable for an establishe...
Full UTHR AnalysisWant More Comparisons?
Run any stock through our deep value analyzer.
Not Financial Advice
This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.